Related references
Note: Only part of the references are listed.Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis
Andrea Fava et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
Guillermo Ruacho et al.
LUPUS SCIENCE & MEDICINE (2022)
Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era
Luisa Safar-Boueri et al.
PEDIATRIC NEPHROLOGY (2021)
FDA approves AstraZeneca's anifrolumab for lupus
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis
Ana Malvar et al.
KIDNEY INTERNATIONAL (2020)
Role of Chemokine (C-X-C Motif) Ligand 10 (CXCL10) in Renal Diseases
Jie Gao et al.
MEDIATORS OF INFLAMMATION (2020)
Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon-γ-Induced Protein 10, BMS-986184, in Healthy Participants to Guide Therapeutic Dosing
Weiguo Cai et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Lupus nephritis
Hans-Joachim Anders et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases
Jiao Jiang et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2020)
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL)
Pietro Merli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus
I-Tsu Chyuan et al.
CELLS (2019)
Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis
Pongpratch Puapatanakul et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Interferon target-gene expression and epigenomic signatures in health and disease
Franck J. Barrat et al.
NATURE IMMUNOLOGY (2019)
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Lars Ronnblom et al.
LUPUS SCIENCE & MEDICINE (2019)
A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy
Marcelo De Rosa et al.
KIDNEY INTERNATIONAL (2018)
The Dual Nature of Type I and Type II Interferons
Amanda J. Lee et al.
FRONTIERS IN IMMUNOLOGY (2018)
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2016)
SERUM AND URINARY INTERFERON-GAMMA-INDUCIBLE PROTEIN 10 IN LUPUS NEPHRITIS
S. I. Nasef et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Serum and Urinary Interferon-Gamma-Inducible Protein 10 in Lupus Nephritis
Ahmed El-Gohary et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2016)
Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015 A Systematic Review and Bayesian Meta-Analysis
Maria G. Tektonidou et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases
Alessandro Antonelli et al.
AUTOIMMUNITY REVIEWS (2014)
Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
Lloyd Mayer et al.
GUT (2014)
Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis
B. Abujam et al.
LUPUS (2013)
Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
M. A. Engel et al.
CURRENT MEDICINAL CHEMISTRY (2012)
CXCR3 ligands: redundant, collaborative and antagonistic functions
Joanna R. Groom et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis
Jianxin Lu et al.
NEPHROLOGY (2011)
MECHANISMS OF DISEASE Systemic Lupus Erythematosus
George C. Tsokos
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CXCR3 Mediates Renal Th1 and Th17 Immune Response in Murine Lupus Nephritis
Oliver M. Steinmetz et al.
JOURNAL OF IMMUNOLOGY (2009)
M-Type Phospholipase A(sub 2) Receptor as Target Antigen in Idiopathic Membranous Nephropathy.
Laurence H. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients
Qiong Fu et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis
Y Avihingsanon et al.
KIDNEY INTERNATIONAL (2006)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Lupus nephritis in African Americans
JP Lea
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2002)
Share Paper
